---
layout: post
title: "Fosun Pharma USA Inc.; Withdrawal of Approval of Abbreviated New Drug Application for Pemoline Tablets, 18.75 Milligrams, 37.5 Milligrams, and 75 Milligrams"
date: 2026-02-05 18:35:50 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-04564
original_published: 2023-03-07 00:00:00 +0000
significance: 8.00
---

# Fosun Pharma USA Inc.; Withdrawal of Approval of Abbreviated New Drug Application for Pemoline Tablets, 18.75 Milligrams, 37.5 Milligrams, and 75 Milligrams

**Published:** February 05, 2026 18:35 UTC
**Source:** Federal Register
**Original Published:** March 07, 2023 00:00 UTC
**Document Number:** 2023-04564

## Summary

The Food and Drug Administration (FDA or Agency) is withdrawing approval of abbreviated new drug application (ANDA) 075286 for pemoline tablets, 18.75 milligrams (mg), 37.5 mg, and 75 mg, held by Fosun Pharma USA Inc. (Fosun), 104 Carnegie Center, Princeton, NJ 08540. Fosun requested that approval of this application be withdrawn and has waived its opportunity for a hearing.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/03/07/2023-04564/fosun-pharma-usa-inc-withdrawal-of-approval-of-abbreviated-new-drug-application-for-pemoline-tablets)
- API: https://www.federalregister.gov/api/v1/documents/2023-04564

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
